19 April 2021
Bernard Courtieu, CEO of IntegraGen said: “2020 was an exceptional year for IntegraGen in several ways. Commercial activities achieved double-digit growth, results were close to breakeven for the second consecutive year, and the company’s cash position was strengthened, despite the considerable impact of the health crisis.”
Click here to (…) »
12 January 2021
IntegraGen announced today its unaudited business figures for the year 2020.
2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »
18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
16 September 2020
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).
09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »
09 July 2020
IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) »
03 April 2020
+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year
IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.
Operating (…) »
26 March 2020
IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…) »
11 March 2020
IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur.
Click here to view press release.
12 January 2020
IntegraGen announced today its unaudited business figures for the year 2019.
2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019. (…) »